Pure Global AI
NCT06082440Not yet recruiting

Study on the Safety and Tolerance of Mesenchymal Stem Cells Mediated by Arthroscopy in Patients With Osteoarthritis

A Single-Arm Clinical Study on the Safety and Tolerance of Human Umbilical Cord Mesenchymal Stem Cells Mediated by Arthroscopy in Patients With Stage II-III Knee Osteoarthritis
First Affiliated Hospital of Wannan Medical CollegePhase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Osteoarthritis, Knee
Drug/Device/Intervention
Human Umbilical Mesenchymal Stem Cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
First Affiliated Hospital of Wannan Medical College
Timeline & enrollment
Phase
Phase 1
Start date
Oct 10, 2023
End date
Jan 10, 2026
Enrollment
18 participants
Primary outcome

Within 4 weeks after treatment, evaluate the incidence and severity of adverse events.,Within 4 weeks after treatment, evaluate the Maximum Tolerable Dose (MTD).

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical
 cord mesenchymal stem cells mediated by arthroscopy in patients with knee osteoarthritis.
 This experiment proposes to enroll 18-22 patients. The experimental drug is human umbilical
 cord mesenchymal stem cells.

ICD-10 classifications
Chronic instability of kneeInjuries to the knee and lower legGonarthrosis [arthrosis of knee]Dislocation, sprain and strain of joints and ligaments of kneeSprain and strain of other and unspecified parts of knee
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06082440
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06082440 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Wannan Medical College and is currently Not yet recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.